Alder BioPharmaceuticals Inc. (ALDR) CEO Randall C. Schatzman Sells 8,181 Shares of Stock
Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) CEO Randall C. Schatzman sold 8,181 shares of the company’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $31.15, for a total value of $254,838.15. Following the sale, the chief executive officer now owns 122,949 shares in the company, valued at approximately $3,829,861.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) opened at 31.47 on Thursday. The stock’s 50 day moving average price is $32.29 and its 200-day moving average price is $28.37. Alder BioPharmaceuticals Inc. has a 12 month low of $15.82 and a 12 month high of $39.43. The firm’s market capitalization is $1.58 billion.
Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its earnings results on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by $0.04. The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $1.14 million. During the same period in the prior year, the business earned ($0.46) EPS. The company’s revenue was up 112900.0% compared to the same quarter last year. On average, equities analysts anticipate that Alder BioPharmaceuticals Inc. will post ($3.33) earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Norges Bank purchased a new position in Alder BioPharmaceuticals during the fourth quarter worth about $10,183,000. Prudential Financial Inc. boosted its position in Alder BioPharmaceuticals by 12.5% in the first quarter. Prudential Financial Inc. now owns 104,100 shares of the biopharmaceutical company’s stock worth $2,549,000 after buying an additional 11,600 shares during the period. BlackRock Fund Advisors boosted its position in Alder BioPharmaceuticals by 4.2% in the first quarter. BlackRock Fund Advisors now owns 1,136,823 shares of the biopharmaceutical company’s stock worth $27,841,000 after buying an additional 45,908 shares during the period. JPMorgan Chase & Co. boosted its position in Alder BioPharmaceuticals by 11.4% in the first quarter. JPMorgan Chase & Co. now owns 349,482 shares of the biopharmaceutical company’s stock worth $8,559,000 after buying an additional 35,883 shares during the period. Finally, State Street Corp boosted its position in Alder BioPharmaceuticals by 20.2% in the first quarter. State Street Corp now owns 1,195,800 shares of the biopharmaceutical company’s stock worth $29,282,000 after buying an additional 200,566 shares during the period.
Several analysts have issued reports on ALDR shares. Jefferies Group restated a “buy” rating on shares of Alder BioPharmaceuticals in a research note on Tuesday, August 23rd. Zacks Investment Research upgraded Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $38.00 price objective on the stock in a research note on Tuesday, September 27th. Finally, Brean Capital started coverage on Alder BioPharmaceuticals in a research note on Friday, September 30th. They set a “buy” rating and a $45.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating, Alder BioPharmaceuticals has a consensus rating of “Buy” and an average target price of $45.00.
About Alder BioPharmaceuticals
Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.
Receive News & Stock Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.